1 / 6

Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE

Phase 2. Treatment Naïve. Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE. Brown A, et al. EASL 2015; Abstract P0771. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Features.

elspeth
Télécharger la présentation

Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentNaïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

  2. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: Features Source: Brown A, et al. EASL 2015; Abstract P0771.

  3. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: Study Design for GT 1 24 0 12 Week n =30 GT2Non-cirrhotic EBR-GZR + RBV SVR12 SVR12 GZR + RBV n =30 n =19 SVR12 GT4, 5, or 6Non-cirrhotic EBR-GZR + RBV EBR-GZR n =19 SVR12 Abbreviations: EBR = Elbasvir; GZR = Grazoprevir; RBV = ribavirin Drug DosingElbasvir (50mg)once dailyGrazoprevir (100 mg)once dailyRibavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Brown A, et al. EASL 2015; Abstract P0771.

  4. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: Baseline Characteristics Source: Brown A, et al. EASL 2015; Abstract P0771.

  5. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: Results C-SCAPE: SVR12 by Genotype and Regimen EBR + GZR + RBV x 12 weeks EBR + GZR + RBV x 12 weeks GZR + RBV x 12 weeks EBR + GZR x 12 weeks 24/30 19/26 10/10 9/10 4/4 1/4 3/4 3/4 Source: Brown A, et al. EASL 2015; Abstract P0771.

  6. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6C-SCAPE Study: Conclusions Source: Brown A, et al. EASL 2015; Abstract P0771.

More Related